Crystalys Therapeutics has initiated patient dosing in its Phase III AMETHYST trial for dotinurad, a next-generation URAT1 inhibitor being developed for progressive gout. The news comes just five days after Swedish Orphan Biovitrum (Sobi) announced positive late-stage data for pozdeutinurad, a direct competitor in the same drug class.
Dotinurad is a once-daily oral therapy designed to lower uric acid levels by inhibiting the URAT1 transporter in the kidney, offering an alternative to standard-of-care allopurinol. The AMETHYST trial is evaluating its efficacy and safety in patients with gout who have an inadequate response to or cannot tolerate allopurinol. Specific enrollment targets and primary endpoints were not disclosed in the source.
Both dotinurad and Sobi's pozdeutinurad belong to the emerging class of selective URAT1 inhibitors, which aim to provide better urate-lowering control with fewer side effects than older therapies. Crystalys believes there remains significant unmet need in the gout market, even with multiple URAT1 candidates advancing through development.
The rapid succession of clinical milestones highlights a competitive landscape for next-generation gout treatments. With pazdeutinurad's Phase III success potentially speeding its path to filing, Crystalys faces pressure to demonstrate differentiation in efficacy or safety to capture market share. Neither company has disclosed specific financial terms or projected pricing for their respective therapies.
Analysts note that the gout treatment market, long dominated by allopurinol and febuxostat, may be poised for transformation as newer agents target higher response rates and better tolerability. However, patient access will depend on favorable reimbursement and head-to-head data against established generics.